Optimizing Cigna Skyrizi Prior Authorization Workflows

Efficiently managing Cigna Skyrizi prior authorization is critical for timely patient access to this IL-23 inhibitor, requiring precise navigation of Cigna Healthcare's medical and pharmacy benefit processes.

For revenue cycle directors and prior authorization coordinators, securing approvals for specialty medications like Skyrizi (risankizumab) from Cigna Healthcare presents unique challenges. Klivira streamlines the complex requirements, from clinical documentation to submission channel selection, to accelerate approval for indications such as plaque psoriasis, psoriatic arthritis, and Crohn's disease.

Navigating Cigna Healthcare's Prior Authorization Channels for Skyrizi

Skyrizi, as a specialty IL-23 inhibitor, typically falls under both medical and pharmacy benefits, depending on the site of administration and payer plan design. Cigna Healthcare directs medical-benefit prior authorization submissions for Skyrizi through its CignaforHCP.com provider portal or via X12 278 transactions through clearinghouses. For pharmacy benefits, particularly for self-administered or retail-dispensed Skyrizi, submissions route through Express Scripts, Evernorth's PBM, which leverages ePA partners like CoverMyMeds and Surescripts.

Specialty Pharmacy and PBM Integration for Risankizumab

Evernorth's Express Scripts manages the pharmacy benefit for Cigna Healthcare members, including specialty medications like risankizumab. Accredo, the specialty pharmacy under Express Scripts, often handles the dispensing and associated prior authorizations for complex injectable medications. Understanding whether Skyrizi is covered under the medical or pharmacy benefit, and the specific submission pathways for each, is crucial for compliant and efficient PA processing.

Essential Documentation for Skyrizi PA with Cigna Healthcare

Detailed clinical notes supporting the diagnosis of plaque psoriasis, psoriatic arthritis, or Crohn's disease.
Documentation of prior therapies, including step therapy requirements, and rationale for Skyrizi initiation.
Evidence of disease severity and progression, aligning with Cigna Healthcare's medical necessity criteria.
Site-of-care justification if administration is outside of a typical outpatient setting.
Adherence to Cigna Healthcare's published coverage policies and medical necessity guidelines, accessible via their provider site.

Electronic Prior Authorization (ePA) for Skyrizi with Evernorth

Klivira integrates directly with Evernorth's established electronic prior authorization capabilities, including connections to Express Scripts via ePA partners like CoverMyMeds and Surescripts. This digital pathway for pharmacy benefit submissions significantly reduces manual effort and accelerates the review process for medications like Skyrizi, improving turnaround times compared to fax or phone submissions.

Understanding Cigna Skyrizi Prior Authorization Denials and Appeals

Common denial reasons for Skyrizi prior authorizations from Cigna Healthcare include insufficient documentation of medical necessity, failure to meet step therapy requirements, or non-formulary status under Express Scripts. Klivira's platform helps proactively identify potential denial triggers. Should a denial occur, Cigna Healthcare documents appeal pathways on its provider portal, including options for peer-to-peer reviews for clinical denials. For Medicare Advantage plans, CMS-0057-F mandates specific turnaround times for appeals.

Frequently asked questions

Which Cigna entity handles Skyrizi prior authorizations for medical vs. pharmacy benefits?

Cigna Healthcare manages prior authorizations for Skyrizi under the medical benefit, typically through the CignaforHCP.com portal. For pharmacy benefits, Evernorth's Express Scripts, and its specialty pharmacy Accredo, handle the PA process, often leveraging ePA platforms.

Are there specific step therapy requirements for Skyrizi with Cigna Healthcare?

Cigna Healthcare's medical necessity criteria and formulary policies for specialty drugs like Skyrizi often include step therapy requirements. It is essential to consult the specific, versioned coverage policy on Cigna Healthcare's provider site to understand the required preceding therapies for plaque psoriasis, psoriatic arthritis, or Crohn's disease.

How does Klivira support electronic prior authorization for Skyrizi with Cigna Healthcare?

Klivira automates the submission of Skyrizi prior authorizations, integrating with Cigna Healthcare's X12 278 pathways for medical benefits and connecting to Evernorth's Express Scripts through ePA partners like CoverMyMeds and Surescripts for pharmacy benefits. This ensures compliance with payer-specific digital submission requirements.

What are the typical turnaround times for Skyrizi prior authorizations with Cigna Healthcare?

Turnaround times vary by plan type and state regulations. For Cigna Healthcare's Medicare Advantage plans, CMS-0057-F mandates standard PA decisions within 72 hours and expedited decisions within 24 hours. Commercial plan timeframes are subject to state-specific minimums.

Where can I find Cigna Healthcare's coverage policies for Skyrizi (risankizumab)?

Cigna Healthcare publishes its medical necessity guidelines and coverage policies on its public provider site, accessible via cigna-coverage-positions. These policies are versioned and dated, and it's crucial to reference the specific policy number and effective date relevant to risankizumab.